Bial Discontinues Pariceract After Phase 2b ACTIVATE Trial Miss
PORTO, Portugal, June 9, 2026 Bial announced topline results from its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract)...
GCase Activator
Advertisement
Advertisement
